Hyperhomocysteinaemia and end stage renal disease

Journal of Nephrology

Volumn 10, Issue 2, 1997, Pages 77-84

  Gupta, Anjan ^a   Robinson, Killian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atherosclerosis; end stage renal disease; homocysteine

Indexed keywords

HOMOCYSTEINE;

ATHEROSCLEROSIS; HUMAN; KIDNEY FAILURE; REVIEW;

ARTERIOSCLEROSIS; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 0030923631     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Chauveau P, Chadefaux B, Coude M, et al. Hyperhomocysteinaemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 (Suppl 4): S72-7.
2. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinaemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121-5.
3. Shemin D, Bostom AG, Verhoef P, et al. Total plasma homocysteine(tHCY) levels and mortality in dialysis patients. (Abstract) J Am Soc Nephrol 1996; 7: 1464.
4. Kunz K, Petitjean P, Lisri M, et al. Cardiovasculasr (CV) morbidity and endothelial dysfunction in chronic hemodialyzed patients (HD-P): is homocysteine (HCY) the missing link? (Abstract) J Am Soc Nephrol 1996; 7: 1453.
5. Jungers P, Chauveau P, Chadefaux B, et al. Hyperhomocysteinemia is associated with arterial occlusive accidents in predialysis chronic renal failure (CRF) patients. (Abstract). J Am Soc Nephrol 1996; 7 (9): 373A.
6. Robinson K, Gupta A, Dennis VW, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-8.
7. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker Inc. 1992; 183-236.
8. Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27 (3): 517-27.
9. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed New York: McGraw-Hill, 1989; 693-734.
10. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
11. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinaeinia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
12. Condon JR, Asatoor AM. Aminoacid metabolism in uraemic patients. Clin Chem Acta 1971; 32: 333-7.
13. Robins AJ, Milewczyk BK, Booth EM, Mallick NP. Plasma aminoacid abnormalities in chronic renal failurre. Clin Chem Acta 1972; 42: 215-7.
14. Cohen BD, Patel H, Kornhauser RS. Alternate reasons for atherogenesis in uremia. Proc Dialysis Transplant Forum 1977; 7: 178-80.
15. Kopple JD, Jones M, Fukuda S, et al. Aminoacid and protein metabolism in renal failure. Am J Clin Nutr 1978; 31: 1532-40.
16. Wilcken DEL, Gupta VJ. Sulphur-containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979; 9: 301-7.
17. Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance hemodialysis. Clin Sci 1980; 58: 427-30.
18. Soria C, Chadefaux B, Coude M, Gaillard O, Kamoun P. Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem 1990; 36: 2137-8.
19. Arnadottir M, Brattström L, Simonsen O, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-40.
20. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-4.
21. Janssen MJFM, van den Berg M, Stehouwer CDA, Boers GHJ. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure. Neth J Med 1995; 46: 244-51.
22. Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
23. Laidlaw SA, Smolin LA, Davidson WD, Kopple JD. Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 1987; 32 (Suppl 22): S191-6.
24. Hultberg B, Andersson A, Arnadottir M. Reduced free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 1995; 70: 62-7.
25. Kang SS, Wong PWK, Bidani A, Milanez S. Plasma protein bound homocystcine in patients requiring chronic hemodialysis (letter). Clin Sci 1983; 65: 335-6.
26. Smolin LA, Laidlaw SA, Kopple JD. Altered plasma free and protein bound sulfur aminoacid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987; 45: 737-43.
27. Brattström L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51-60.
28. Jacobsen DW, Gatautis VJ, Green et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate levels in healthy subjects. Clin Chem 1994; 40: 873-81.
29. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-37.
30. Genest JJ Jr, Mcnamara JR, Upson B, et al. Prevalence of hyperhomocysteinemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11: 1129-36.
31. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
32. Fodinger M, Mannhalter C, Pabinger-Fasching I, et al. Is hyperhomocysteinemia in hemodialysis (HD) patients associated with a mutation of the methylenetetrahydrofolate reductase gene? (Abstract). J Am Soc Nephrol 1996; 7 (9): 1817A.
33. Greene R, Chong Y, Jacobsen D, et al. Serum homocysteine is high in hypothyroidism: a possible link with coronary artery disease. Ir J Med Sci 1995; 164: 27.
34. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981; 61: 743-9.
35. Ceballos I, Chauveau P, Guerin V, et al. Early alteration of plasma free aminoacids in chronic renal failure. Clin Chem Acta 1990; 188: 101-8.
36. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
37. Sturman JA, Rassin DK, Gaull GE. Distribution of transulphuration enzymes in various organs and species. Int J Biochem 1970; 1: 251-3.
38. Gupta A, Moustapha A, Jacobsen DW, et al. Hyperhomocysteinemia in patients udergoing heart transplantation (submitted for publication).
39. Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81: 466-74.
40. Moustapha A, Gupta A, Robinson K, et al. Hyperhomocysteinaemia and renal failure: metabolic determinants and effects of mode of dialysis (submitted for publication).
41. 6 and hemodialysis: the impact of high-flux/high-efficiency analysis and review of the literature. Am J Kid Dis 1996; 27: 680-6.
42. 6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int 1974; 5: 233.
43. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Neph Dial Trap 1994; 9: 1103-8.
44. Ibels LS, Stewart JH, Mahony JF, et al. Occlusive renal disease in ureamic and hemodialysis patients and renal transplant recipients. Q J Med 1977; XLVI: 197-214.
45. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981; 61: 743-9.
46. Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509-12.
47. Fogarty DG, Woodside J, Lightbody JH, et al. Plasma homocysteine in renal transplant recipients. J Am Soc Nephrol 1996; 7 (9): 3421A.
48. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
49. Kodgers GM, Kane WM. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
50. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci 1994; 91: 6369-73.
51. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
52. Loscalzo J. The oxidant stress of hyperhomocys(e)inemia. J Clin Invest 1996; 98: 5-7.
53. Bray CL. Discussion. In: Brett EM. Homocystinuria with epilepsy. Proc R Soc Med 1960; 59: 484.
54. Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukot Med 1986; 22: 349-56.
55. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency. Possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.
56. Bostom AG, Shemin D, Lapane KL, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-52.
57. Chauveau P, Chadefaux B, Kolko A, et al. Hyperhomocysteinemia in hemodialyzed patients: effects of folate supplementation and dialysis membranes. J Am Soc Nephrol 1996; 7 (9): 1132A.
58. Bostom AG, Shemin D, Nadeau MR, et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation (letter). Atherosclerosis 1995; 113: 129-32.
59. Bostom AG, Shemin D, Youburn, et al. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120: 241-4.